ANEB Anebulo Pharmaceuticals, Inc.
Healthcare$0.50+8.70%ClosedMarket Cap: $20.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.38
P/S
0.00
EV/EBITDA
-1.17
DCF Value
$0.34
FCF Yield
-31.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-74.6%
ROA
-84.7%
ROIC
-102.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $0.00 | NaN% | $-2.6M | $-2.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.3M | $-2.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-2.3M | $-2.1M | $— | — |
| FY null | $0.00 | NaN% | $-9.2M | $-8.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.9M | $-1.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.6M | $-2.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.4M | $-2.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.3M | $-1.3M | $— | — |
| FY null | $0.00 | NaN% | $-8.3M | $-8.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.7M | $-1.7M | $— | — |
| Q2 2024 | $0.00 | NaN% | $-2.8M | $-2.7M | $-0.11 | — |
| Q1 2024 | $0.00 | NaN% | $-2.5M | $-2.5M | $-0.10 | — |